GlassScriptPhysician profile
Urmee Siraj
NPI 1801891114
$2,999.28
in general payments reported to CMS, 2019-2025
20 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $72.89 · 2021: $228 · 2022: $347 · 2023: $446 · 2024: $765 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,987.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.25 | 2020-2025 | Linzess, Viberzi, Rinvoq |
| Pfizer INC. | $599.20 | 2019-2025 | |
| Janssen Biotech, INC. | $257.54 | 2024 | Stelara, Tremfya |
| Genzyme Corporation | $253.84 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Qol Medical, LLC | $124.52 | 2022 | |
| Gilead Sciences, INC. | $93.21 | 2022-2025 | Epclusa |
| Braintree Laboratories, INC. | $76.47 | 2025 | Suflave, Sutab |
| Ethicon US, LLC | $74.00 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $57.84 | 2019 | |
| Celltrion USA INC. | $41.63 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.63 | 2023-2025 | Xifaxan |
| Celgene Corporation | $26.52 | 2022 | |
| Amgen INC. | $21.84 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.31 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $20.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $15.29 | 2022 | |
| Alfasigma USA, INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urmee Siraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.